178 related articles for article (PubMed ID: 16885125)
1. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha.
Vyas SP; Rawat M; Rawat A; Mahor S; Gupta PN
Drug Dev Ind Pharm; 2006 Jul; 32(6):699-707. PubMed ID: 16885125
[TBL] [Abstract][Full Text] [Related]
2. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
[TBL] [Abstract][Full Text] [Related]
3. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
Bailon P; Palleroni A; Schaffer CA; Spence CL; Fung WJ; Porter JE; Ehrlich GK; Pan W; Xu ZX; Modi MW; Farid A; Berthold W; Graves M
Bioconjug Chem; 2001; 12(2):195-202. PubMed ID: 11312680
[TBL] [Abstract][Full Text] [Related]
4. Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.
Qiu J; Wei XH; Geng F; Liu R; Zhang JW; Xu YH
Acta Pharmacol Sin; 2005 Nov; 26(11):1395-401. PubMed ID: 16225764
[TBL] [Abstract][Full Text] [Related]
5. PEG-interferon conjugates: effects of length and structure of linker.
Sabar MF; Kausar S; Zafar AU
Pak J Pharm Sci; 2013 Mar; 26(2):425-30. PubMed ID: 23455218
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of tramadol PEG-coated multivesicular liposomes for sustained release.
He S; Zhu J; Xie F
Pharmazie; 2010 Jul; 65(7):467-70. PubMed ID: 20662312
[TBL] [Abstract][Full Text] [Related]
7. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres.
Diwan M; Park TG
Int J Pharm; 2003 Feb; 252(1-2):111-22. PubMed ID: 12550786
[TBL] [Abstract][Full Text] [Related]
9. Intramuscular injection of palmitic acid-conjugated Exendin-4 loaded multivesicular liposomes for long-acting and improving
Tian H; Chang M; Lyu Y; Dong N; Yu N; Yin T; Zhang Y; He H; Gou J; Tang X
Expert Opin Drug Deliv; 2024; 21(1):169-185. PubMed ID: 38224039
[TBL] [Abstract][Full Text] [Related]
10. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferons for the treatment of chronic hepatitis C infection.
Luxon BA; Grace M; Brassard D; Bordens R
Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
[TBL] [Abstract][Full Text] [Related]
12. Pegylation of IFN-alpha and antiviral activity.
Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
[TBL] [Abstract][Full Text] [Related]
13. [Interferon alpha-2b modified with polyethylene glycol].
Wu Y; Zhai Y; Lei J; Ma G; Su Z
Sheng Wu Gong Cheng Xue Bao; 2008 Sep; 24(9):1658-63. PubMed ID: 19160853
[TBL] [Abstract][Full Text] [Related]
14. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
15. In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles.
Feczkó T; Fodor-Kardos A; Sivakumaran M; Haque Shubhra QT
Nanomedicine (Lond); 2016 Aug; 11(16):2029-34. PubMed ID: 27462975
[TBL] [Abstract][Full Text] [Related]
16. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
Boulestin A; Kamar N; Legrand-Abravanel F; Sandres-Saune K; Alric L; Vinel JP; Rostaing L; Izopet J
Antimicrob Agents Chemother; 2004 Sep; 48(9):3610-2. PubMed ID: 15328140
[TBL] [Abstract][Full Text] [Related]
17. [Preparation of cationic vancomycin hydrochloride multivesicular liposomes and its quality].
Yang D; Xu Y; Li F; Liu H; He X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Apr; 27(4):443-8. PubMed ID: 23757873
[TBL] [Abstract][Full Text] [Related]
18. Multivesicular Liposomes for the Sustained Release of Angiotensin I-Converting Enzyme (ACE) Inhibitory Peptides from Peanuts: Design, Characterization, and In Vitro Evaluation.
Li N; Shi A; Wang Q; Zhang G
Molecules; 2019 May; 24(9):. PubMed ID: 31060345
[TBL] [Abstract][Full Text] [Related]
19. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization.
Mu H; Wang Y; Chu Y; Jiang Y; Hua H; Chu L; Wang K; Wang A; Liu W; Li Y; Fu F; Sun K
Drug Deliv; 2018 Nov; 25(1):1372-1383. PubMed ID: 29869520
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
